Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar-Apr:17 Suppl 1:36-43.
doi: 10.4158/EP10310.RA.

Parathyroid cancer

Affiliations
Review

Parathyroid cancer

Sandy H Fang et al. Endocr Pract. 2011 Mar-Apr.

Abstract

Objective: To review the current knowledge pertaining to the etiology, molecular pathogenesis, and management of parathyroid carcinoma, a rare presentation of primary hyperparathyroidism.

Methods: The existing MEDLINE English-language literature was reviewed using the search terms "parathyroid" and "carcinoma" or "cancer."

Results: Parathyroid cancer is a rare endocrine tumor accounting for a small proportion of cases of primary hyperparathyroidism. Recent database studies indicate increasing incidence rates. Its etiology is unknown, although numerous molecular alterations have been described, and the tumors also occur in association with germline mutations in the CDC73 gene. Most affected patients present with severe hypercalcemia; however, the diagnosis can be challenging. Complete surgical resection remains the mainstay of treatment and provides the best chance of cure, although data from small series suggest that external beam radiation may also reduce the high recurrence rates. No effective chemotherapy regimens are currently available. A significant number of patients develop recurrent disease and need additional procedures; however, long-term survival is possible with palliative surgery. Medical management of chronic and debilitating hypercalcemia with calcimimetics is often necessary and is an important adjunct in patients with recurrent and metastatic disease.

Conclusions: Further elucidation of the molecular pathogenesis of parathyroid carcinomas will enhance our understanding of etiology and behavior of this uncommon entity. Future research must be directed at identifying more effective therapies for this condition.

PubMed Disclaimer

Similar articles

  • Parathyroid carcinoma.
    Rodgers SE, Perrier ND. Rodgers SE, et al. Curr Opin Oncol. 2006 Jan;18(1):16-22. doi: 10.1097/01.cco.0000198019.53606.2b. Curr Opin Oncol. 2006. PMID: 16357559 Review.
  • A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
    Kapur A, Singh N, Mete O, Hegele RA, Fantus IG. Kapur A, et al. Endocr Pathol. 2018 Dec;29(4):374-379. doi: 10.1007/s12022-018-9552-5. Endocr Pathol. 2018. PMID: 30361844
  • Parathyroid carcinoma.
    Mittendorf EA, McHenry CR. Mittendorf EA, et al. J Surg Oncol. 2005 Mar 1;89(3):136-42. doi: 10.1002/jso.20182. J Surg Oncol. 2005. PMID: 15719375 Review.
  • Parathyroid carcinoma: molecular therapeutic targets.
    Marini F, Giusti F, Palmini G, Aurilia C, Donati S, Brandi ML. Marini F, et al. Endocrine. 2023 Sep;81(3):409-418. doi: 10.1007/s12020-023-03376-w. Epub 2023 May 9. Endocrine. 2023. PMID: 37160841 Review.
  • Parathyroid carcinoma.
    Salcuni AS, Cetani F, Guarnieri V, Nicastro V, Romagnoli E, de Martino D, Scillitani A, Cole DEC. Salcuni AS, et al. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):877-889. doi: 10.1016/j.beem.2018.11.002. Epub 2018 Dec 1. Best Pract Res Clin Endocrinol Metab. 2018. PMID: 30551989 Review.

Cited by

Substances

LinkOut - more resources